Kiniksa Pharmaceuticals International, plc
KNSA
Rang in aandelen
#2962
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Aandeelprijs
$79.61
Marktkapitalisatie
$6.21B
Verandering (1 dag)
1.30%
Verandering (1 jaar)
106.02%
Land
GB
Handel Kiniksa Pharmaceuticals International, plc (KNSA)
Categorie
Healthcare
EPS voor Kiniksa Pharmaceuticals International, plc (KNSA)
EPS per June 2026 TTM: $1.07
Volgens de laatste financiële rapporten en de aandelenkoers van Kiniksa Pharmaceuticals International, plc is de huidige EPS van het bedrijf (TTM) $1.07. Eind 2023 had het bedrijf een EPS van $0.20, een daling ten opzichte van de EPS van 2022 die $2.64 bedroeg.
EPS-geschiedenis van Kiniksa Pharmaceuticals International, plc van 2016 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $1.07 | -278.33% |
| 2024 | $-0.60 | -400.00% |
| 2023 | $0.20 | -92.42% |
| 2022 | $2.64 | -214.78% |
| 2021 | $-2.30 | -11.88% |
| 2020 | $-2.61 | -12.71% |
| 2019 | $-2.99 | -14.33% |
| 2018 | $-3.49 | 74.50% |
| 2017 | $-2.00 | 170.27% |
| 2016 | $-0.74 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $2.41 | 125.23% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $0.52 | -51.40% |
US
|
